Cartesian Therapeutics Stock Forecast
NASDAQ: RNACHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:28 AM ET
RNAC analyst consensus
Consensus (7 analysts)
strong_buy
Avg. price target
$33.67+398.73%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Cartesian Therapeutics (2026-10-08), 7 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $33.67, with a high estimate of $44.00 and a low estimate of $16.00. The average target implies upside of 398.7% from the current price of $6.75.
The spread between the highest and lowest targets is 175.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RNAC.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 6 | 86% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $16.00 | +137.00% |
| Average target | $33.67 | +398.73% |
| High target | $44.00 | +551.75% |